08.08.2023 | Commentry
Do We Still Need 5α-Reductase Inhibitors for Patients with Benign Prostatic Hyperplasia After the PARTEM Study?
verfasst von:
Tiago Bilhim
Erschienen in:
CardioVascular and Interventional Radiology
|
Ausgabe 10/2023
Einloggen, um Zugang zu erhalten
Excerpt
Would like to congratulate the French interventional radiology teams who recently published a relevant randomized controlled trial comparing prostatic artery embolization (PAE) with medical therapy for patients with benign prostatic hyperplasia (BPH) [
1]. The
Prostatic
ARTery
Embolization versus
Medical therapy–PARTEM—study was a multicenter randomized trial enrolling patients from 10 hospitals, across France that started in 2016 and was completed in 2022. Included patients needed to have bothersome lower urinary tract symptoms (LUTS) with an international prostatic symptom score (IPSS) > 11 points and quality of life (QoL) score > 3 points and a prostate volume ≥ 50 mL. All included patients needed to have at least 1 month duration of medical therapy with alpha-blockers but no prior usage of 5α-Reductase Inhibitors (5-ARIs). After randomization to PAE, patients stopped the alpha-blockers, whereas patients randomized to combination therapy (CT) received both alpha-blockers and 5-ARIs. Thus, non-medicated PAE patients were compared with patients receiving medical CT at 9 months (
n = 44 PAE;
n = 43 CT) and 2 years (
n = 42 PAE;
n = 38 CT). The primary outcome measure compared between groups was the reduction in IPSS score at 9 months follow-up. …
